With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.
The resulting compound (220 mg, 0.580 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (110 mg, 0.580 mmol) to afford the desired title compound (132 mg, yield 45%) as a white solid. 1H-NMR (CDCl3, 400 MHz) delta: 12.57 and 10.15 (1H, brs), 7.98 (1H, d, J=4.6 Hz), 7.65-7.53 (4H, m), 7.37 (1H, brs), 6.99 (2H, d, J=8.6 Hz), 5.07 (1H, t, J=7.3 Hz), 4.72-4.65 (1H, m), 4.03-3.62 (5H, m), 2.36-2.10 (2H, m), 2.02-1.80 (3H, m), 1.12 (3H, d, J=6.8 Hz), 1.11 (3H, d, J=6.8 Hz). IR (ATR) cm-1: 1685, 1630, 1610, 1515, 1445, 1320, 1250. MS (ESI, m/z): 517 (M+H)+. Anal. Calcd for C26H27F3N4O4: C, 60.46; H, 5.27; N, 10.85. Found: C, 60.23; H, 5.23; N, 10.82., 1204-75-7
The synthetic route of 1204-75-7 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider